Tania Kapoor

Tania Kapoor

Auto-generated profile, based on publicly available information

Tania Kapoor

The Rockefeller University, Laboratory of Molecular Immunology, New York, NY 10065, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MAMarianna Agudelo
Marianna Agudelo
Martin PalusMartin Palus
Martin Palus
JKJennifer R. Keeffe
Jennifer R. Keeffe
FBFilippo Bianchini
Filippo Bianchini
Pavel SvobodaPavel Svoboda
Pavel Svoboda
MNMichel C. Nussenzweig
Michel C. Nussenzweig
Tick-borne encephalitis virus (TBEV) is an emerging human pathogen that causes potentially fatal disease with no specific treatment. Mouse monoclonal antibodies are protective against TBEV, but little is known about the human antibody response to infection. Here, we report on the human neutralizing antibody response to TBEV in a cohort of infected and vaccinated individuals. Expanded clones of memory B cells expressed closely related anti-envelope domain III (EDIII) antibodies in both groups of volunteers. However, the most potent neutralizing antibodies, with IC50s below 1 ng/ml, were found only in individuals who recovered from natural infection. These antibodies also neutralized other tick-borne flaviviruses, including Langat, louping ill, Omsk hemorrhagic fever, Kyasanur forest disease, and Powassan viruses. Structural analysis revealed a conserved epitope near the lateral ridge of EDIII adjoining the EDI–EDIII hinge region. Prophylactic or early therapeutic antibody administration was effective at low doses in mice that were lethally infected with TBEV.

24 March 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
KRKoen K.A. Van Rompay
Koen K.A. Van Rompay
LCLark L. Coffey
Lark L. Coffey
TKTania Kapoor
Tania Kapoor
AGAnna Gazumyan
Anna Gazumyan
RKRebekah I. Keesler
Rebekah I. Keesler
DRDavide F. Robbiani
Davide F. Robbiani
Significance: Zika virus (ZIKV) infection during pregnancy can cause fetal abnormalities. Vaccines against ZIKV are under development, but because of potential safety concerns due to disease-enhancing antibodies, and the time required by active immunization to induce protective antibodies, there is a need to explore alternative strategies. Recombinant monoclonal antibodies can be modified to prevent enhancement of infection, and thus could be an efficacious and safe alternative to vaccines to confer rapid protection. We show that prophylactic administration of two engineered antibodies, Z004 and Z021, to pregnant macaques partially protects against fetal neurologic damage and limits vertical transmission of ZIKV.

8 April 2024 in Vector-Borne and Zoonotic Diseases
Verified
Journal Article
Closed access
TKTania Kapoor
Tania Kapoor
LMLilly Murray
Lilly Murray
MKMara Kuvaldina
Mara Kuvaldina
CJCaroline S. Jiang
Caroline S. Jiang
APAvery A. Peace
Avery A. Peace
MMMargaret R. MacDonald
Margaret R. MacDonald
Introduction: Lyme disease (LD) affects ∼476,000 people each year in the United States. Symptoms are variable and include rash and flu-like symptoms. Reasons for the wide variation in disease outcomes are unknown. Powassan virus (POWV) is a tick-borne flavivirus that causes disease ranging from asymptomatic infection to encephalitis, neurologic damage, and death. POWV and LD geographic case distributions overlap, with Ixodes species ticks as the common vectors. Clinical ramifications of coinfection or sequential infection are unknown. Objectives: This study's primary objective was to determine the prevalence of POWV-reactive antibodies in sera samples collected from previously studied cohorts of individuals with self-reported LD history residing in the Northeastern United States. As a secondary objective, we studied clinical differences between people with self-reported LD history and low versus high POWV antibody levels. Methods: We used an enzyme-linked immunosorbent assay (ELISA) to quantify IgG directed at the POWV envelope (E) protein domain III in 538 samples from individuals with self-reported LD history and 16 community controls. The samples were also tested with an ELISA assay to quantify IgG directed at the POWV NS1 protein. Results: The percentage of individuals with LD history and possible evidence of POWV exposure varied depending on the assay utilized. We found no significant difference in clinical symptoms between those with low or high POWV IgG levels in the in-house assay. Congruence of the EDIII and NS1 assays was low with only 12% of those positive in the in-house EDIII ELISA testing positive in the POWV NS1 ELISA. Conclusions: The results highlight the difficulty in flavivirus diagnostic testing, particularly in the retrospective detection of flavivirus exposure. The findings suggest that a prospective study with symptomatic patients using approved clinical testing is necessary to address the incidence and clinical implications of LD and POWV co-infection or sequential infection.

6 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
TRTomás Cervantes Rincón
Tomás Cervantes Rincón
TFTereza Frckova
Tereza Frckova
ZCZaria I. Contejean
Zaria I. Contejean
JOJasmine Oberti-Cantergiani
Jasmine Oberti-Cantergiani
KGKevin Groen
Kevin Groen
DRDavide F. Robbiani
Davide F. Robbiani
West Nile virus (WNV) is a mosquito-borne pathogen of global concern that can cause fatal neuroinvasive disease. No specific prophylaxis or treatment exists for WNV or related orthoflavivirus infections, and the determinants of human disease severity remain poorly understood. Here, we report that neutralizing autoantibodies against type I interferons do not impair antiviral antibody development. Among the fully human monoclonal antibodies with potent neutralizing activity against WNV that were discovered, W010 targets a unique epitope within the envelope protein domain III (EDIII) and confers both pre- and post-exposure protection in a murine WNV model, even when interferon signaling is impaired. A second protective antibody, W014, exhibits broad cross-neutralization of other pathogenic orthoflavivirus members, including Japanese encephalitis virus, Murray Valley encephalitis virus, Saint Louis encephalitis virus, and Usutu virus. These findings identify key neutralizing epitopes on WNV EDIII and provide candidates for the development of antibody-based interventions against encephalitic orthoflavivirus infections.